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Hematopoietic stem cell transplantation (HSCT) is widely used for the cure of a variety of 
hematological malignant and non-malignant diseases, metabolic diseases and immunological 
disorders. The conditioning regimen, isolation, restriction of activities and complications 
that might occur in this procedure provoke significant psychic, physical and psychosocial 
distress(1,2). When returning to their daily living activities, many patients complain about 
fatigue, worsening functionality and reduced participation in activities that may require 
physical effort such as work, recreation and domestic activities(3,4). 
The most commonly reported functional deficits in this population are fatigue (5-7), 
lost of physical performance(8,9) and loss of muscle strength(5,10-13). Clinical events such 
as mucositis, acute and chronic graft versus host disease (GVHD), nutrition disorders, 
infections, emotional problems and stress may culminate in worse physical and 
psychological conditions(14,15). 
Functions associated to physical capacity are a useful indicator of good health and 
longevity when related to disease processes; this is the main target of rehabilitation(16,17). 
Functional measures are commonly used in epidemiologic studies of incapacity and in the 
evaluation of rehabilitation programs. They are considered important variables for clinical 
research and can provide supplementary information for medical diagnosis(18). 
Function capacity is directly linked to physical status and is the most important domain 
to be considered in quality of life (QOL)(19). Functional evaluations can be used to assess 
many physical aspects such as aerobic conditioning(6,14,16,20), muscle strength(5,12,20-22), functional 
capacity(6,8,12,23), mobility(16) and QOL(7,23-25).
There is a variety of measures and tools available to carry out functional evaluations 
which involve different domains. These range from ability and physical skill tests (walking 
tests, treadmill tests, strength tests, mobility tests, etc) to self-report questionnaires (to 
evaluate specific areas – such as pain and daily life activities - or general health related 
status – such as the quality of life short form 36 questionnaire), and self-reports related 
to psychic conditions. 
The aim of this study was to prospectively evaluate all domains of physical capacity that 
interfere in functionality before and after HSCT.
 Objective: To perform a function evaluation of patients before and after hematopoietic stem cell transplantation.
Methods: From November 2008 to November 2010, 29 female (58%) and 21 male patients (42%) with median 
age of 48 years (range: 24-67) were enrolled in this study. Data collection was performed before and after 
autologous or allogeneic hematopoietic stem cell transplantation. Evaluation instruments included the 2-minute 
walking test to evaluate gait performance with assessment of the oxygen saturation, heart rate and Borg Scale 
before and after the test; grip strength for strength evaluation, Schober Test for spine mobility testing and 
maximum and adapted activity scores of the Human Activity Profile questionnaire to test functionality in daily 
activities.
Results: Fifty patients were evaluated at baseline; six did not undergo hematopoietic stem cell transplantation 
(three died, one refused and two were excluded). Thus 44/50 (88% - 21 allogeneic and 23 autologous) 
transplantations were performed. Only 33 of the 44 patients (75%) performed evaluations after transplantation 
(nine died and two were excluded). Of the patients who performed both evaluations, significantly lower values 
were found in the evaluation after transplantation for the 2-minute walking test (p-value = 0.004), grip strength 
of both right and left hands (p-value = 0.004 and p-value < 0.0001, respectively), the Schober Test, and 
maximum and adapted activity scores (p-value < 0.0001). The heart rate was higher (p-value = 0.01) before the 
2-minute walking test and oxygen saturation was higher (p-value = 0.02) after. 
Conclusion: Statistical differences indicate functional impairment after transplantation showing physical 
losses in this population.
Keywords: Rehabilitation; Physical examination; Hematopoietic stem cell transplantation
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Methods
Selection of subjects
This prospective study enrolled all consecutive patients 
between 18 and 70 years old with malignant hematological diseases, 
who underwent autologous or allogeneic HSCT at the HSCT 
unit of the Hospital das Clinicas of the Universidade Estadual de 
Campinas – UNICAMP from November 2008 to November 2010. 
The patients were included if they were submitted to high-dose or 
reduced-dose allogeneic HSCT with HLA-identical related donors 
with cells harvested from bone marrow or peripheral blood. The 
conditioning regimens and prophylaxis for GVHD were selected 
according to existing protocols at the University Hospital.
The exclusion criteria were previous HSCT and non-malignant, 
neurologic, psychiatric and orthopedic diseases. Four patients were not 
included in the study: two were diagnosed with depressive disorder, 
one was submitted to lower limb amputation and one did not agree to 
participate in the study. All consecutive patients who met the inclusion 
criteria and that agreed to participate in this study gave their written 
informed consent. The protocol was designed in accordance with the 
requirements for research involving human subjects and approved by 
the Institutional Review Board (protocol number 784/2008).
For cases of fever, infection, severe thrombocytopenia and 
neutropenia at the time of evaluation, the tests were postponed, 
when possible, until after the patient had recovered. Any conditions 
that contraindicate exercise or those specified in the guidelines for 
the six-minute walking test of the American Thoracic Society(26) 
were also considered for the two-minute walking test (2MWT). 
Study procedure 
Data collection and the evaluation of functions were performed 
before HSCT (Phase 1) and after discharge on an outpatient basis 
(Phase 2). Anthropometric data were collected and the body mass 
index (BMI) was calculated. The instruments used in the evaluation 
were: 1. the 2MWT, an evaluation of walking capacity performed on 
a 20-meter indoor track to evaluate function of gait performance and 
aerobic conditioning; 2. oxygen saturation (SaO2); 3. heart rate (HR) 
assessed by a pulse oximeter; 4. the Borg Scale (BS), a 0 to 10 scale 
of fatigue sensations, to assess fatigue before and after the 2MWT; 
5. grip strength test (GS) for hand strength evaluation, performed 
three times for each hand with small intervals between, using a hand 
hydraulic dynamometer; 6. the Schober Test (ST), a flexion trunk test 
to evaluate lumbar spine mobility; 7. maximum and adapted activity 
score (MAS and AAS), variables of the Human Activity Profile 
(HAP) questionnaire that evaluate functioning related to daily life 
activities with the energy expenditure needed for each activity. 
Statistical analysis
Descriptive analyses were performed for all variables. The 
paired sample t-test was applied for physical and functional variables 
to assure that the means represent the same group at different times. 
The independent sample t-test was used to compare the type of HSCT. 
P-value < 0.05 was considered significant and the SPSS (Statistical 
Package of Social Sciences) version 14.0 was used for data analysis.
Results
As intention to treat, 50 patients were enrolled in the present 
study. The median age was 48 (24-67) years and 29 (58%) of 
the patients were female. Forty-four out of 50 (88%) patients 
underwent HSCT [21 (48%) allogeneic and 23 (52%) autologous]. 
Six of 50 (12%) patients were not submitted to HSCT as three died 
before the procedure, one refused to participate due to complete 
remission before HSCT and two were excluded; one had exclusion 
criteria and the other due to an unacceptable donor. Data on the 
patients and HSCT characteristics are shown in Table 1.
Table 1 - Patients and transplant characteristics (n = 50) 
Variable
Age (years) - mean ± SD/median (range) 46 ± 13 / 48 (24-67)
Gender (male/female) - n 21 / 29
Weight (kg) - mean ± SD/median (range) 70 ± 19 / 66.8 (35-121.6)
Height (m) - mean ± SD/median (range) 1.65 ± 13 / 1.7 (1.2-1.9)
BMI (kg/m2) - mean ± SD/median (range) 25.7 ± 6.2 / 24.8 (15.8-44)
Diagnosis at transplant - n  
  Acute Leukemias 16
  Lymphomas 17
  Myelomas 8
  Others 9
Pre-transplantation risk category - n  
  Low risk 15
  High risk 35
Transplant type (n)*  
  Autologous 23
  Allogeneic 21
Conditioning regimen type - n  
  Autologous HSCT  
  BEAM 13
  Melphalan 8
  Bu + CY 2
High dose – Allogeneic HSCT  
  Bu + CY 6
  Bu + CY + VP 3
  ICT + CY + VP 1
  Bu + Fludarabine 1
Reduced Intensity – Allogeneic HSCT  
  TBI + Fludarabine 2
  Melphalan + Fludarabine 8
GVHD prophylaxis - n  
  MTX + CsA 19
  MMF + CsA 2
Months from diagnosis to HSCT - median (range)  
  Autologous HSCT 20 (6-211)
  Allogeneic HSCT 5 (2-123)
SD: standard deviation; BMI: body mass index; Others: 3 chronic lymphocytic 
leukemia, 3 myelodysplastic syndrome and 1 myelofibrosis (myeloproliferative 
disorders), 2 chronic myeloid leukemia (CML); Low risk: complete remission or 
chronic phase CML; High risk: partial remission, relapse, progression, accelerate phase 
for CML; BEAM: carmustine, etoposide, cytarabine and melphalan; Bu: busulfan; CY: 
cyclophosphamide; VP: etoposide; TBI: total body irradiation; GVHD: graft versus host 
disease; MTX: methotrexate; CsA: cyclosporine; MMF: mycophenolate mofetil
*Six patients did not perform transplant
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Table 2 - Functional outcomes in Phase 1 for allogeneic and autologous hematopoietic stem 







Age (years) - median (range) 45 (25-65) 24 (24-67) 0.22
Gender (male) - n 11 (52) 9 (39) 0.54
Weight (kg) - median (range) 66.4 (35-121) 67.3 (43-113) 0.96
BMI (kg/m2) - median (range) 24.9 (15.8-35.9) 24.6 (18.9-44.4) 0.84
Hemoglobin (g/dL) - median (range) 10.1 (7.0-14.8) 11.4 (6.9-15-2) 0.20
2MWT (meters) - median (range) 178 (113-224) 178 (107-224) 0.98
SaO2
  Before 2MWT (%) - median (range) 98 (93-100) 99 (94-100) 0.92
  After 2MWT (%) - median (range) 98 (91-100) 97 (91-100) 0.44
Heart rate
  Before 2MWT (bpm) - median (range) 87 (63-131) 79 (57-112) 0.18
  After 2MWT (bpm) - median (range) 116 (73-152) 102 (69-143) 0.15
Borg score
  Before 2MWT, median (range) 0 (0-3) 0 (0-5) 0.66
  After 2MWT, median (range) 3 (0-10) 2 (0-8) 0.12
  Schober’s test (cm) - median (range) 6 (2-10) 6 (2-9) 0.68
Grip Strength
  Right hand (kg) - median (range) 30.3 (14.7-55) 33.3 (19.0-56) 0.61
  Left hand (kg) - median (range) 28.0 (14.0-47) 32.0 (16.0-49) 0.62
  MAS - median (range) 53 (21-91) 56 (26-84) 0.15
  ASS - median (range) 41 (-13-91) 48 (-1-82) 0.31
* p-value from independent-samples test;
HSCT: hematopoietic stem cell transplantation; BMI: body mass index; 2MWT: 2-minute walking test; SaO2: 
oxygen saturation; bpm: beats per minute; MAS: maximum activity scale; AAS: adapted activity scale.
Thirty-three of 44 (75%) patients performed evaluations in 
Phase 1 (before) and Phase 2 (after HSCT). Eleven (25%) patients 
did not complete the Phase 2 evaluations as nine died and two 
were excluded due to physical and clinical impairment. Figure 
1 shows the flowchart of patients’ distribution for phase 1 and 
phase 2. The Phase 1 functional evaluation of patients who died 
after HSCT and thus did not perform the Phase 2 evaluation, was 
not statistically different compared with those who performed 
both evaluations.
Figure 1 - Flowchart showing patient distribution before and after HSCT
50 patientsPre HSCT
44 patients HSCT












The Phase 1 functional evaluation was compared between 
allogeneic and autologous HSCT patients and the functional 
status was statistically similar (Table 2).
For the 33 patients who performed both evaluations, 18 
patients underwent autologous and 15 underwent allogeneic 
HSCT. When the transplant outcomes were analyzed for 
patients who performed both Phase 1 and Phase 2 functional 
evaluations, the median length of total parenteral nutrition 
(TPN), the length of antibiotic therapy, and time to neutrophil 
and platelet engraftment were longer in the allogeneic HSCT 
group, resulting in a longer hospital stay. The transplant 
outcomes are presented in Table 3. 
Functional outcomes comparing Phase 1 and Phase 2 
evaluations
The median time in days from the Phase 1 evaluation to 
HSCT was 26 days (range: 7-188) and from HSCT to Phase 2 
evaluation was 41 days (range: 17-187). The expectation was to 
evaluate patients until 60 days after HSCT and only three patients 
exceeded this timeframe.
Of the patients who performed both evaluations, there were 
significantly lower values in Phase 2 for weight and BMI (p-value 
< 0.0001), 2MWT (p-value = 0.004), ST (p-value < 0.0001), GS 
for both right and left hands (p-value = 0.004 and < 0.0001, 
respectively), MAS and AAS (p-value < 0.0001 for both) and 
higher values for HR before 2MWT (p-value = 0.01) and SaO2 
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after 2MWT (p-value = 0.02). No significant difference was found 
for HR after 2MWT, SaO2 before 2MWT, Borg Scale before and 
after 2MWT and hemoglobin. The functional evaluation results 
comparing Phase 1 and Phase 2 are presented in Table 4.
Discussion 
This study showed that patients acquire physical losses after 
autologous and allogeneic HSCT. The focus was on the physical 
components of function with the applied tools evaluating most 
of variables that compose physical capacity such as strength, 
aerobic conditioning, mobility, fatigue and QOL. 
Fatigue and loss of strength in performing daily life activities 
are the first symptoms of functional deficit(5). Cancer-related 
fatigue is described as one of the most prevalent and debilitating 
side effects of cancer and its treatment(27-29). In the current study, 
the 2MWT associated to oximetry and the adapted Borg Scale 
were used to assess aerobic conditioning and fatigue before and 
after exercise and the hand grip test to assess muscle strength. 
Although the origin of fatigue is considered multifactorial and 
its etiology is complex and not completely understood, common 
sense implies that it is strongly related to physical factors(30). 
The 2MWT is a simple gait performance exam. Here it 
was demonstrated that this is a good instrument to evaluate 
gait performance in these patients; the results demonstrated 
impairment in walking after transplant. It is less encumbered by 
fatigue, but it demonstrates cardiopulmonary and musculoskeletal 
adaptations during gait performance(31). The 2MWT was also 
reliable to evaluate other populations as a good indicator in 
the decline of function demonstrating gait performance(32,33), 
Table 4 - Functional outcomes for patients who performed both evaluation (n= 33)
Outcomes Phase 1 Phase 2 P-value*
Weight (kg) - median (range) 67.3 (35-121.6) 64.8 (35.5-113.8) < 0.0001
BMI (kg/m2) - median (range) 26 (15.9-44.4) 23.8 (17.5-44.7) < 0.0001
Hemoglobin (g/dL) - median (range) 11.1 (6.9-15.2) 10.7 (8.1-13.1) 0.09
2MW (m) - median (range) 181 (106-224) 165 (97-227) 0.004
SaO2
  Before 2MWT (%) - median (range) 99 (95-100) 99 (92-100) 0.48
  After 2MWT (%) - median (range) 97 (91-99) 98 (92-100) 0.02
Heart rate
  Before 2MWT (bpm) - median (range) 87 (57-131) 111 (70-152) 0.01
  After 2MWT  (bpm) - median (range) 96 (73-126) 123 (76-156) 0.20
Borg scale
  Before 2MWT - median (range) 0 (0-5) 3 (0-10) 0.06
  After 2MWT - median (range) 1 (0-5) 3 (0-8) 0.74
  Schober’s test, median (range), cm 6.5 (2-9) 5.5 (1.5-9.5) < 0.0001
Grip Strength
  Right hand (kg) - median (range) 31 (19-55) 31 (16-47) 0.004
  Left hand (kg) - median (range) 31 (18-55) 27 (16-47) < 0.0001
MAS - median (range) 54 (25-84) 42 (15-85) < 0.0001
ASS - median (range) 45 (-1-81) 22 (-16-82) < 0.0001
* P-value - Paired sample t-test
HSCT: hematopoietic stem cell transplantation; BMI: body mass index; SaO2: oxygen saturation; bpm: beats 
per minute; MAS: maximum activity scale; AAS: adapted activity scale







Mucositis II-III - n (%) 4 (26.6%) 12 (66.6%) 0.03
Mucositis IV - n (%) 8 (53.3%) 3 (16.6%)
TPN, median (days) - median (range) 9 (0-16) 0 (0-8) 0.001
Antibiotics (days) - median (range) 11 (0-29) 7 (0-24) 0.11
Neutrophil engraftment (days) - median (range) 18 (11-26) 10 (8-13) < 0.0001
Platelets engraftment (days) - median (range) 15 (11-40) 14 (11-20) 0.03
Days to discharge (days) - median (range) 25 (14-36) 15 (11-34) 0.001
Alive - n (%) 7 (47) 16 (89) 0.02
* P-value from independent-samples test;
TPN: total parenteral nutrition.
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including patients with chronic GVHD(20). Although fatigue is a 
very common symptom after transplant, the Borg scale was not 
significantly different before and after transplant. However, the 
HR before 2MWT was higher. According to Gillis & Donovan(34) 
maintaining bed rest causes a chain of cardiac events that 
increases resting HR and provokes orthostatic intolerance with 
postural hypotension occurring due to the diminished blood 
volume and/or changes in autonomic responses. The increased 
HR before the 2 MWT found in our cohort of patients might be 
explained by bed rest. 
The patients in this study presented reductions in spine 
mobility after HSCT. Muscle atrophy, restricted activities and 
being bedridden also have consequences on the overall range 
of motion. Schober’s test is commonly used to evaluate lumbar 
spine mobility in patients with lumbar pain or lumbar joint 
impairment(35). Suesada et al.(36) investigated spine mobility in 
patients submitted to short-term hospitalization using the Stibor 
and Schober’s tests and showed a decrease in mobility (p-value 
< 0.0001) which strongly suggests that only a short period of bed 
confinement is likely to reduce pelvic and spine mobility. As trunk 
flexion requires great joint mobility and muscle activation(37) this 
test gives an idea of whether or not the overall mobility is affected. 
There was a statistically significant loss of weight and 
BMI in Phase 2 (p-value < 0.0001) and the grip test showed an 
important reduction in muscles of both hands after transplant. 
Chemotherapy, toxicities involved in HSCT and reduced 
food intake contribute to an energy imbalance that provokes 
loss of lean mass and weight(14). Not only corticosteroids and 
chemotherapy induce fatigue, but also the neoplasia itself and 
the resulting production of inflammatory cytokines in the disease 
process(5). In addition, oxidative stress from chemotherapy and 
radiation treatment, along with iron overload from multiple 
blood transfusions may contribute to muscle dysfunction 
through an excessive production of reactive species(11). White 
et al.(38) demonstrated that patients before HSCT had lower 
plasma concentrations of glutathione peroxidase, an important 
component of the circulating antioxidant system, compared with 
controls. Hence, muscle atrophy followed by strength loss and 
functional impairment are expected. Hand strength appears to be 
valid measurement to assess overall strength loss with this being 
confirmed by a great number of studies that investigated patients 
with other diseases and clinical conditions(20,39-42). 
One useful and widely used instrument with cancer patients 
is the QOL questionnaire. Courneya & Friedenreich, in a literature 
review about exercise and cancer, observed that all authors used 
some QOL instrument(19) to evaluate the effect of interventions. 
The choice in this study was the HAP questionnaire. Created by 
Daughton et al.(43) this instrument evaluates functioning in daily 
life activities. It correlates 94 possible activities with the maximum 
consumption of oxygen needed to perform each activity. In this 
study there was a significant reduction in functioning as detected 
by the variables assessed by the HAP questionnaire (MAS and 
AAS). Herzberg et al.(8) observed that, within one year of HSCT, 
the HAP was more sensitive to detect functional deficits resulting 
from chronic GVHD manifestations and steroid myopathy than 
the FACT-BMT and the SF-36 questionnaires. There was also a 
strong correlation between these questionnaires.
It is well known and documented that patients with 
cancer go through great physical and psychosocial stress since 
diagnosis, causing a variety of signs and symptoms that may 
last for some time after treatment(3,7,44-47) even when results of 
treatment are positive(3,28). Patients submitted to HSCT have an 
extra dose of factors that contribute even more to disability, such 
as conditioning regiments, restrictions before, during and after 
treatment and complications inherent to the procedure (including 
acute and chronic GVHD) that can occur in the early and late 
periods after the procedure. 
Physical domain functions are considered predictors of 
longevity and good health and their parameters are being used 
in clinical trials as primary or secondary endpoints associated 
to clinical evaluation(16,17). The instruments used in this study 
were chosen with the main objective of using one tool for each 
physical domain with simple and effective evaluations that can be 
performed in clinical settings. 
The results of comparing physical parameters between the 
allogeneic and autologous groups in the Phase 1 evaluation were not 
statistically different, showing that the functional status of allogeneic 
and autologous patients are similar. Differences were observed for 
clinical parameters at Phase 2. Thus, an important limitation of our 
study was that our sample was not large enough to compare the Phase 
2 results between the two groups. The different types of procedure 
may impact on function differently, but the analyses were not 
possible due to the small number of patients. Further investigations 
should be considered with larger sample sizes as some of the findings 
of this study may be confirmed or reinforced. 
This study only verified physical impairment but it is known 
that psychic conditions might influence the physical performance 
and these variables should be investigated in future studies. 
Conclusion 
Significant differences identify decreases in aerobic 
conditioning before and after physical stress, declines in functioning 
and gait performance, reduction of muscle strength and spine 
flexibility and diminished functioning in daily activities after HSCT. 
The intensity and specificity may guide preventive measures and 
conduct a better rehabilitation program in the post-HSCT period.
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